Feedback regulation of gonadotropins by androgens in rats: is 5 alpha-reduction involved?
The action of testosterone (T) on the sex accessory organs, such as ventral prostate (VP) and seminal vesicles (SV) is amplified by its 5 alpha-reduction to dihydrotestosterone (DHT). This does not happen in the case of muscle (levator ani, LA) which contains little or no 5 alpha-reductase activity. It has been suggested that the regulation of gonadotropins by T may also be mediated by its 5 alpha-reduced metabolites. We investigated this question by utilizing two types of androgens: (1) T and 17 alpha-methyl-testosterone (17MT), whose potency increases following 5 alpha-reduction; and (2) 19-nortestosterone (NT) and 17 alpha-methyl-19-nortestosterone (17MNT) whose potency decreases following 5 alpha-reduction. Castrated rats were used to investigate the ability of these androgens to stimulate VP, and SV (androgenic action) and LA growth (anabolic action) and to suppress the post-castration rise in LH levels. In addition, modification of these actions by a 5 alpha-reductase inhibitor (5 alpha-RI) was studied. Compared to T, NT was approximately 5 times less potent in stimulating VP and SV. By contrast, it was twice as potent as T in stimulating LA growth. Similarly, 17MNT was 5 times less androgenic but twice as anabolic as 17MT. The antigonadotropic potency of both the 19-nor compounds was 2-3 times greater than that of their respective 19-methylated parent compounds. The similarity in their anabolic and antigonadotropic potency suggested that 5 alpha-reduction is not a factor in their antigonadotropic action. This was confirmed by the use of the 5 alpha-RI. Treatment of rats receiving the androgens with 5 alpha-RI showed that it decreases the androgenic activity of T and 17MT while it increases the androgenic activity of NT and 17 MNT. In all cases the anabolic activity and the antigonadotropic potency remained unchanged. It is concluded that the regulation of pituitary gonadotropin secretion by T does not depend upon its 5 alpha-reduction to DHT.
Center for Biomedical Research, Population Council, New York, NY 10021.
N
N
Kumar
K
K
Sundaram
C W
CW
Bardin
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000378:metabolism*; D058891:5-alpha Reductase Inhibitors; D000728:Androgens / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D005246:Feedback; D018120:Finasteride / Q000031:analogs & derivatives / Q000494:pharmacology; D006062:Gonadotropins / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009132:Muscles / Q000187:drug effects; D009277:Nandrolone / Q000031:analogs & derivatives / Q000378:metabolism; D009919:Orchiectomy; D010084:Oxidation-Reduction; D011467:Prostate / Q000187:drug effects*; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D012669:Seminal Vesicles / Q000187:drug effects*; D013739:Testosterone / Q000031:analogs & derivatives / Q000378:metabolism
D058891:5-alpha Reductase Inhibitors; D000728:Androgens; D006062:Gonadotropins; D013739:Testosterone; D018120:Finasteride; D009277:Nandrolone; D007986:Luteinizing Hormone; C092075:N,N-diethyl-3-oxo-4-azaandrost-1-ene-17-carboxamide; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase